SCHEMBL6844873

SCHEMBL6844873

CCOC(=O)c1c(CSc2ccccc2C)ccc(Br)c1OC

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 5/20 0.46
MAPT P10636 7/20 0.46
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
ALOX15 P16050 2/20 0.46
USP2 O75604 1/20 0.46
SMN1; SMN2 Q16637 4/20 0.42
RAB9A P51151 4/20 0.42
LMNA P02545 3/20 0.42
TSHR P16473 2/20 0.42
MAPK1 P28482 1/20 0.42
NPSR1 Q6W5P4 2/20 0.40
TDP1 Q9NUW8 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
GAA P10253 2/20 0.37
CA12 O43570 1/20 0.37
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
CA7 P43166 1/20 0.37
CA9 Q16790 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18801058 0.90 ALOX5 (0.48) ALOX5MAPTSMN1; SMN2RAB9ALMNA
SCHEMBL1648072 0.86 MAPT (0.47) ALOX5MAPTMEN1KMT2AALOX15
SCHEMBL1648249 0.82 MAPT (0.42) ALOX5MAPTMEN1KMT2ASMN1; SMN2
SCHEMBL1648293 0.81 KMT2A (0.39) MAPTMEN1KMT2AALOX15USP2
SCHEMBL18801099 0.80 ALOX5 (0.48) ALOX5MAPTMEN1KMT2AALOX15
SCHEMBL1648170 0.79 MTNR1A (0.44) ALOX5MEN1KMT2ASMN1; SMN2RAB9A
SCHEMBL1648273 0.79 CA12 (0.41) ALOX5MAPTMEN1KMT2ASMN1; SMN2
SCHEMBL18801340 0.78 MAPT (0.43) ALOX5MAPTMEN1KMT2AALOX15
SCHEMBL1648422 0.78 ALOX5 (0.52) ALOX5MAPTMEN1KMT2AALOX15
SCHEMBL1648309 0.78 LMNA (0.40) ALOX5MAPTMEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2486004-B1 SULPHONE COMPOUNDS FOR USE IN THE TREATMENT OF OBESITY ZAFGEN INC (US) 2017-05-03 EP disclosed
US-9067905-B2 Sulphone compounds and methods of making and using same ZAFGEN, INC. (US) 2015-06-30 US disclosed
US-9067905-B2 Sulphone compounds and methods of making and using same ZAFGEN, INC. (US) 2015-06-30 US disclosed
US-20130053364-A1 Sulphone Compounds and Methods of Making and Using Same ZAFGEN, INC. 2013-02-28 US disclosed
US-20130053364-A1 Sulphone Compounds and Methods of Making and Using Same ZAFGEN, INC. 2013-02-28 US disclosed
WO-2011044506-A2 SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME ZAFGEN CORPORATION (US) 2011-04-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130053364-A1 Sulphone Compounds and Methods of Making and Using Same METAP2, DNPEP, STS ALOX5 951/4885MAPT 3145/4885MEN1 1603/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.